Latest ArticlesDue to many factors, such as point mutations in the ligand-binding domain of the androgen receptor(AR) and expression of splice variants, the existing treatment methods for prostate cancer have been successively ineffective. Therefore, new strategies for prostate cancer treatment are urgently needed. In recent years, significant progress has been made in targeted protein degradation technology. For example, AR degraders, which are expected to solve the problem of drug resistance in clinical prostate cancer patients, can block the androgen receptor signaling pathway by promoting AR degradation. This review focuses on the proteolysis targeting chimeras(PROTAC) technology and small molecule degraders targeting AR, and summarizes the research progress in this field from the mechanism of action and representative compounds, respectively. Compared with the inherent druggability defects of PROTAC molecules, small molecule AR degraders have more advantages and are now becoming the leading research direction for the treatment of prostate cancer.
The classic resolution of racemates is one of the choices for production of chiral compounds in large scale. Due to the advantages of inexpensive and readily available of resolution agents, mature methods, simple operation, and ease of large-scale production, resolution still plays a role in the pharmaceutical industry. However, its main disadvantage is that half of the products are unwanted enantiomers, resulting in significant waste. Recycle process of resolution-racemization is a direct and effective way to remedy this disadvantage. In this paper, the applications of recycle process of resolution-racemization in synthesis of chiral drugs are reviewed based on the different mechanisms of racemization(carbanion/carbocation mechanism and mechanism of elimination-reduction).
Protein-protein interactions(PPIs) and the protein complexes formed through the interactions are essential for the cells to perform various basic functions. Most important life activities, such as DNA replication and transcription, protein synthesis and transport, cellular signal transduction and regulation of substance metabolism, are maintained through dense PPI networks. Genetic mutations, epigenetic alterations, and changes in the cellular microenvironment can interfere with PPI patterns or directly induce protein binding to form new tumor-specific interactions, leading to the genesis, progression, invasion and metastasis of tumors. In recent years, significant progress has been made in developing antineoplastics targeting PPI, some of which are in clinical trials or have been approved for marketing. There is growing evidence that drugs targeting specific PPI may have higher specificity and efficacy than those that inhibit the activity of proto-oncogene proteins and offer therapeutic opportunities to cure specific cancers. This paper systematically reviews the research progress of antineoplastics targeting PPI, and describes the challenges and countermeasures for the research of antineoplastics targeting PPI to provide a reference for their development.
The incidence of mental disorders is high and has been increased year by year, and antipsychotics are still the main effective methods for treatment of mental disorders at present. However, traditional routes of administration(oral, injection, etc.) cannot fully meet clinical needs due to the limitations of high frequency of medication, large fluctuation in blood drug concentrations, more adverse reactions, and poor patient compliance. Transdermal drug delivery system(TDDS) is a non-invasive drug delivery method that can continuously deliver drugs, maintain stable blood drug concentrations for a long time, and discontinue the drug administration at any time. TDDS can avoid the liver first-pass effect and gastrointestinal irritation, reduce dose-related side effects of oral administration, and with better medication compliance. This paper reviews the latest research results and clinical trials of TDDS in the treatment of mental disorders, and addresses key points to consider in clinical studies of this kind of products, hoping to provide a reference for the pharmaceutical and clinical research of antipsychotics.
Compared with traditional inactivated vaccines, mRNA vaccines have strong immunogenicity and can activate both humoral and cellular immunity. In addition, it has the advantages of a short development cycle, broad neutralization breadth, low cost, and a relatively simple manufacturing process that can be rapidly scaled to respond to sudden and rapidly mutating pandemic outbreaks. As a new vaccine technology, mRNA vaccines have many novel features and challenges. Taking the three coronavirus disease 2019(COVID-19) vaccines, BNT162b2 from Pfizer/BioNTech, mRNA-1273 from Moderna, and ARCoV developed by several Chinese institutions, as examples, this paper summarizes and analyzes the development and manufacturing strategy for mRNA vaccines in terms of antigen selection, nucleoside modification, and lipid nanoparticles(LNP) formulation preparation. The current challenges and future directions are discussed to contribute to a better understanding of mRNA vaccine technology.
Terbutaline sulfate(1) is a selective β2 adrenoreceptor agonist for the treatment of bronchial asthma. In this paper, a novel synthetic process for 1 and its crystal form B was reported. 1-[3,5-Bis(phenylmethoxy)phenyl]-2-bromoethan-1-one(3) was obtained from 3,5-dibenzyloxyacetophenone(2) with copper(Ⅱ) bromide by bromination.1-[3,5-Bis(benzyloxy)phenyl]-2-bromoethanol(4) was synthesized directly by the reduction of 3 with potassium borohydride in methanol. The bromine atom in 4 was substituted with tert-butylamine to give 1-[3,5-bis(benzyloxy)-phenyl]-2-(tert-butylamino)ethanol(5). After purification, 5 was hydrogenated in the catalysis of Pd/C and then salification with sulfuric acid to obtain 1. The crystal form B of 1 was obtained by recrystallization in the mixture of acetone and water in a total yield of 42%. In this process, the materials are inexpensive and easily available. This process has been tested by pilot-scale experiment, which is suitable for industrial production.
Using dimethyl 4-isobutoxyisophthalate(SM) as raw material to generate ammonolysis reaction for giving 4-isobutoxyisophthalamide(2), 4-isobutoxyisophthalonitrile(3) was generated by dehydration of 2, and the yield of this two-step reaction was 87.9%. After the addition of 3 and thioacetamide, it was cyclized with ethyl chloroacetoacetate to produce ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate(5), which was hydrolyzed in an alkaline solution and acidified to obtain febuxostat(1). The total yield was 54.9%(based on SM). The process simplifies the synthesis route of 1, reduces the use of cyanide and other highly toxic chemicals, and its reaction conditions are mild. It is suitable for industrial production of 1.
In this study, the synthesis of minodronic acid by phosphorylation was improved. Started from(imidazolo[1,2-a]pyridin-3-yl)acetic acid(2), the phosphorylation was carried out only with phosphorus trichloride in methanesulfonic acid(as solvent). The product was obtained in a yield of 82.4% and a purity of 99.82%. The process did not use phosphorous acid and any organic solvent, so the heterogeneous reaction state was avoided. These reaction conditions were mild, and the production cost was reduced.